Form 4: Atai Life Sciences Director Acquires Stock Options

Director Scott Braunstein acquired 206,000 stock options in Atai Life Sciences N.V. on June 13, 2024.

Summary

• Scott Braunstein, a director of ATAI Life Sciences N.V., acquired 206,000 stock options on June 13, 2024.
• The exercise price of these options is $1.34.
• The options vest in installments, starting with 1/3rd on June 13, 2025, and the remainder in 24 equal monthly installments, fully vesting by June 13, 2027.
• The options expire on June 13, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a common practice. The director's acquisition could be seen as a positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common practice in the biotech industry to incentivize and align the interests of company directors and management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 1/3rd after one year and the remainder over the subsequent two years is a fairly typical vesting arrangement.
• Comparable companies like Compass Pathways or Mind Medicine also utilize stock options as part of their executive compensation packages.

Key Dates